U.S. markets open in 2 hours 46 minutes
  • S&P Futures

    4,563.75
    -1.50 (-0.03%)
     
  • Dow Futures

    35,650.00
    +6.00 (+0.02%)
     
  • Nasdaq Futures

    15,532.50
    -12.50 (-0.08%)
     
  • Russell 2000 Futures

    2,284.20
    -9.70 (-0.42%)
     
  • Crude Oil

    83.65
    -1.00 (-1.18%)
     
  • Gold

    1,788.40
    -5.00 (-0.28%)
     
  • Silver

    24.01
    -0.07 (-0.30%)
     
  • EUR/USD

    1.1594
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    1.6190
    0.0000 (0.00%)
     
  • Vix

    16.13
    +0.89 (+5.84%)
     
  • GBP/USD

    1.3723
    -0.0041 (-0.30%)
     
  • USD/JPY

    113.7300
    -0.3990 (-0.35%)
     
  • BTC-USD

    58,879.96
    -4,000.96 (-6.36%)
     
  • CMC Crypto 200

    1,412.47
    -92.68 (-6.16%)
     
  • FTSE 100

    7,263.47
    -14.15 (-0.19%)
     
  • Nikkei 225

    29,098.24
    -7.77 (-0.03%)
     

SHAREHOLDER ALERT: SRAC ATHA ITRM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / August 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Stable Road Acquisition Corp. (NASDAQ:SRAC)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/stable-road-acquisition-corp-loss-submission-form?prid=18620&wire=1
Lead Plaintiff Deadline: September 13, 2021
Class Period: October 7, 2020 - July 13, 2021

Allegations against SRAC include that: (a) Stable Road's acquistion target, Momentus's 2019 test of its key technology, a water plasma thruster, had failed to meet Momentus's own public and internal pre-launch criteria for success, and was conducted on a prototype that was not designed to generate commercially significant amounts of thrust; (b) the U.S. government had conveyed that it considered Momentus's Chief Executive Officer a national security threat, jeopardizing his continued leadership of Momentus and Momentus's launch schedule and business prospects; (c) consequently, the revenue projections and business and operational plans provided to investors regarding Momentus and the commercial viability and timeline of its products were materially false and misleading and lacked a reasonable basis in fact; and (d) Stable Road had failed to conduct appropriate due diligence of Momentus and its business operations and defendants had materially misrepresented the due diligence activities being conducted by Stable Road executives and its sponsor in connection with the merger.

Athira Pharma, Inc. (NASDAQ:ATHA)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/athira-pharma-inc-loss-submission-form?prid=18620&wire=1
Lead Plaintiff Deadline: August 24, 2021
This lawsuit is on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company's registration statement issued in connection with the Company's September 2020 initial public offering priced at $17.00 per share.

Allegations against ATHA include that: (1) the research conducted by Defendant Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.

Iterum Therapeutics Plc (NASDAQ:ITRM)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=18620&wire=1
Lead Plaintiff Deadline: October 4, 2021
Class Period: November 30, 2020 - July 23, 2021

Allegations against ITRM include that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/660148/SHAREHOLDER-ALERT-SRAC-ATHA-ITRM-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines